Intellia Therapeutics, Inc. Segments Disclosure
16. Segment Information
The accounting policies for the segment are the same as those described in Note 2, “Summary of Significant Accounting Policies.” The CODM evaluates the performance of the operating segment and allocates resources based on net loss that also is reported on the consolidated statements of operations and comprehensive loss. The CODM uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources. The measure of the operating segment assets is reported on the consolidated balance sheets as total assets.
The following table summarizes the reportable segment’s financial information:
|
|
Year Ended December 31, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
|
2023 |
|
|||
Collaboration |
|
$ |
67,671 |
|
|
$ |
57,877 |
|
|
|
$ |
36,275 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|||
Research and development: |
|
|
|
|
|
|
|
|
|
|
|||
External development expenses - nex-z |
|
|
90,458 |
|
|
|
69,793 |
|
|
|
|
54,454 |
|
External development expenses - lonvo-z |
|
|
47,748 |
|
|
|
42,173 |
|
|
|
|
24,560 |
|
Other research and development (1) (2) |
|
|
250,655 |
|
|
|
354,345 |
|
|
|
|
356,055 |
|
Total research and development |
|
|
388,861 |
|
|
|
466,311 |
|
|
|
|
435,069 |
|
General and administrative (3) |
|
|
119,800 |
|
|
|
125,829 |
|
|
|
|
116,497 |
|
Interest income |
|
|
(29,195 |
) |
|
|
(47,807 |
) |
|
|
|
(49,832 |
) |
Loss from equity method investment |
|
|
- |
|
|
|
- |
|
|
|
|
15,633 |
|
Other segment information (4) |
|
|
899 |
|
|
|
32,565 |
|
|
|
|
100 |
|
Segment and consolidated net loss |
|
$ |
(412,694 |
) |
|
$ |
(519,021 |
) |
|
|
$ |
(481,192 |
) |
Depreciation and amortization expense totaled $9.8 million, $10.3 million and $9.0 million for the years ended December 31, 2025, 2024 and 2023, respectively.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.